Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mingmu Xunxi Decoction for meibomian gland dysfunction
ChiCTR-IIR-17012663Phase 4Not yet recruiting
- Sponsor
- Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University
- Start
- Dec 2017
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Mingmu Xunxi Decoction in meibomian gland dysfunction (MGD) (2 arms), sponsored by Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University. Primary endpoint: Ocular Surface Disease Index at 4 months. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
Mingmu Xunxi Decoction
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on ChiCTR-IIR-17012663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012663.